Austin Health | MedPath

Decade-Long UK Registry Reveals Key Insights into Idiopathic Pulmonary Fibrosis Management and Future Directions

a month ago

• The British Thoracic Society's analysis of the UK Idiopathic Pulmonary Fibrosis Registry provides the first comprehensive long-term data on over 5,000 IPF cases across 64 UK hospitals. • Key findings include significant diagnostic delays with 60% of patients experiencing symptoms for over a year before their first clinic visit, and a shift in antifibrotic treatment preferences from pirfenidone to nintedanib after 2017. • Experts are now advocating for a shift from consensus-based criteria toward personalized, data-driven approaches for early diagnosis and treatment, with initiatives like the global PRIME-PPF study aiming to refine risk stratification.

Largest Whole-Exome Sequencing Study Uncovers New Genetic Links to Epilepsy Subtypes

7 months ago

• A large-scale whole-exome sequencing study involving 21,000 epilepsy patients and 33,000 controls has identified new genetic links to various epilepsy subtypes. • The study highlights the significant role of genes encoding ion channels in multiple epilepsy subtypes, including epileptic encephalopathies and generalized and focal epilepsies. • Researchers found subtype-specific genetic contributions, offering data-driven insights for understanding epilepsy biology and developing tailored diagnostic and treatment approaches. • The Epi25 Collaborative's findings suggest potential therapeutic targets related to neuronal communication and synaptic transmission, with data accessible via an interactive browser.

Telix's Illuccix Receives Expanded Approval in Australia and Canada for PSMA-Targeted Therapy Selection

8 months ago

• The Australian TGA has approved Illuccix for selecting metastatic prostate cancer patients for PSMA-targeted radionuclide therapy. • Health Canada has also approved Illuccix for identifying progressive metastatic castration-resistant prostate cancer (mCRPC) patients for Pluvicto treatment. • Illuccix is a PSMA-PET imaging agent that helps doctors detect prostate cancer and determine patient eligibility for PSMA-targeted therapy. • These approvals expand Illuccix's clinical utility, improving access to advanced prostate cancer imaging and informed treatment decisions.